Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2009

December 11, 2009 Pharmaceuticals

Launch of "Erizas ® Capsule for Nasal spray 400µg" for the treatment of allergic rhinitis, a first once daily dry powder type steroid nasal spray in Japan

Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) have launched today the first once daily dry powder type steroid nasal spray, “Erizas® Capsule for Nasal spray 400µg” (generic name: dexamethasone cipecilate) for the treatment of allergic rhinitis in Japan.

“Erizas® Capsule for Nasal spray 400µg” is a dry powder formulation which contains the novel steroid, discovered in Japan, as an active ingredient.  It is contained in a capsule and sprayed into nasal cavities by using a special device for nasal spray (separately sold). 

This product has the following features.
- It is the first once daily dry powder type steroid nasal spray in Japan
- It can improve three nasal symptoms of allergic rhinitis (sneezing, nasal discharge, and nasal congestion).
- It is a dry powder formulation free from preservative, and causes less local irritation and no dripping off from nasal cavities.

In the clinical studies conducted in Japan, beneficial efficacy on three nasal symptoms of allergic rhinitis (sneezing, nasal discharge, and nasal congestion) and high safety after once daily treatment with this product were confirmed.  This product is a dry powder formulation free from additives such as preservatives contained in a capsule and sprayed into the nasal cavities by using a special device for nasal spray.

This product increases the level of convenience in use due to once daily administration.  In addition, this product has features such as no dripping off from nasal cavities and less local irritation after being applied.

Nippon Shinyaku position the otorhinolaryngology as one of their focus targets for R&D and marketing, and are marketing “Baynas® Tablets”, “Livostin® Nasal Solution 0.025mg 112metered sprays”, and “Livostin® Eye Drops 0.025%” in the field of allergic rhinitis and conjunctivitis like pollen allergy.

By the launch of “Erizas® Capsule for Nasal spray 400µg”, Nippon Shinyaku expect to contribute more to the treatment of allergic rhinitis

Brand name:   “Erizas® Capsule for Nasal spray 400µg”
Manufactured and distributed by:   Nippon Shinyaku Co., Ltd.
Approval number:   22100AMX02248000
Composition:   400µg of dexamethasone cipecilate is contained in a capsule.  Lactose hydrate is used as an additive.
Generic name:   Dexamethasone cipecilate
Indication:    Allergic rhinitis
Dosage and administration:   Generally, one capsule (dexamethasone cipecilate 400µg) a time is sprayed into the nasal cavities by using a special device for nasal spray in adults.
Approval date: October 16, 2009
NHI price listing date: December 11, 2009
NHI price: 139.1Yen / capsule
Package: PTP 70 capsules (PTP 7capsules×10)